Abstract
Percutaneous coronary angioplasty started a revolution by providing a mechanical means of relieving angina. Abrupt vessel closure and restenosis emerged as its major limitations. Bare-metal stents dramatically reduced acute vessel closure, but restenosis, although significantly reduced, remained a clinical problem. Drug-eluting stents mitigated the problem of restenosis to a large extent. However, a small but significant increase in very-late stent thrombosis rates have been noted. Newer stents have been introduced in order to improve the efficacy and safety of stent implantation. The everolimus-eluting Xience V™ stent has been extensively evaluated in the SPIRIT clinical trial program. This article summarizes the various studies of this program and their impact on clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.